Related Experiment Video

Updated: Jan 13, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.4K

Precision management of atorvastatin: Cross-sectional analysis of genetic polymorphisms

Razan Ibrahim1, Mohanad Odeh2, Eyad Mallah1

  • 1Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan.

Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University
|January 5, 2026
PubMed

Insights

This study developed a reliable LC-MS/MS method to measure atorvastatin in plasma. Genetic variants like CYP2D6-4 significantly impact atorvastatin levels, supporting personalized hyperlipidemia treatment.

Area of Science:

  • Pharmacology
  • Clinical Chemistry
  • Genetics

Background:

  • Hyperlipidemia is a key risk factor for cardiovascular diseases.
  • Genetic variants (e.g., CYP2D6-4) influence atorvastatin metabolism and effectiveness.
  • Personalized drug monitoring is crucial for managing hyperlipidemia.

Purpose of the Study:

  • Develop and validate an LC-MS/MS method for quantifying atorvastatin in human plasma.
  • Investigate the impact of genetic polymorphisms, specifically CYP2D6-4, on atorvastatin plasma concentrations.
  • Enhance personalized therapeutic drug monitoring and lipid profile management.

Main Methods:

  • Quantification of atorvastatin using Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS).
  • Genotyping using Polymerase Chain Reaction (PCR)-based methods.
  • Statistical analysis to correlate plasma atorvastatin levels with genetic variants.

Main Results:

  • The LC-MS/MS method demonstrated high accuracy, precision, linearity, and stability.
  • Higher atorvastatin plasma concentrations were associated with the CYP2D6-4 genetic variant.
  • The analytical method was validated for reliable clinical sample measurement.

Conclusions:

  • A robust LC-MS/MS method for atorvastatin quantification in plasma was successfully developed and validated.
  • The strong link between CYP2D6-4 and atorvastatin levels underscores the importance of pharmacogenetic dosing.
  • Integrating pharmacogenetics, particularly in the Jordanian population, can improve atorvastatin therapy safety, efficacy, and individualization.
Abstract

Keywords:
atorvastatingenotypehyperlipidemiapolymorphismstatins

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.2K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.6K

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
194
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
165
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
269
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.9K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196